KRAS inhibitor 11

Research use only, not for human use.

KRAS inhibitor 11 is a first-in-class, high-affinity, noncovalent allosteric KRAS inhibitor.

KRAS inhibitor 11 is a first-in-class, high-affinity, noncovalent allosteric KRAS inhibitor, disrupts KRAS-Raf interaction with Kd of 1.2 uM; binds to activated KRAS with sub-micromolar affinity and disrupts effector binding, thereby inhibiting KRAS signaling and cancer cell growth; dose-dependently decreases both p-ERK and p-cRaf levels in BHK cells expressing KRASG12D and KRASG12V, suggesting inhibition of RAS signaling via the MAPK pathway.

Western Blot Analysis Cell Line:BHK cells stably expressing KRASG12D Concentration:0.01, 0.1, 0.5 1, 5 μM Incubation Time:Result:Decreased the p-ERK levels at >1μM.

——

——

MAPK/ERK Signaling

Ras

Ras

——

——

900897-56-5

413.525

C25H27N5O

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (120.92 mM)

CC1=NN2C(=CC(=NC2=C1C3=CC=CC=C3)C4=CC=CC=C4)N5CCN(CC5)CCO

2-[4-(8-methyl-3,9-diphenyl-2,6,7-triazabicyclo[4.3.0]nona-2,4,7,9-tetraen-5-yl)piperazin-1-yl]ethanol

(-20℃)

With Ice Pack

≥ 2 years